Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 6/20 | 0.42 |
| ▸ | DRD3 | P35462 | 4/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | DRD2 | P14416 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4281899 | 0.84 | TDP1 (0.49) | HTR6MEN1KMT2APKMPOLB | |
| SCHEMBL4287742 | 0.81 | HTR6 (0.39) | HTR6DRD3CYP2C9MEN1KMT2A | |
| SCHEMBL4287257 | 0.78 | KMT2A (0.53) | MEN1KMT2APOLBALDH1A1MAPK1 | |
| SCHEMBL4285751 | 0.76 | AURKA (0.47) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL4285746 | 0.73 | AURKA (0.47) | ALDH1A1L3MBTL1SMN1; SMN2 | |
| SCHEMBL17877194 | 0.70 | BRD4 (0.54) | MEN1KMT2ALMNA | |
| SCHEMBL4946816 | 0.69 | PKM (0.43) | MEN1KMT2APKMPOLBALDH1A1 | |
| SCHEMBL2919887 | 0.69 | AURKA (0.63) | — | |
| SCHEMBL4281894 | 0.68 | TDP1 (0.46) | MEN1KMT2APKMPOLBTSHR | |
| SCHEMBL2694482 | 0.67 | MEN1 (0.76) | HTR6DRD3CYP2C9MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090136513-A1 | BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L (IT) | 2009-05-28 | — | — | US | claimed |
| US-9012487-B2 | Bicyclo-pyrazoles active as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2015-04-21 | — | — | US | disclosed |
| US-20090136513-A1 | BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L (IT) | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090136513-A1 | BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS | MAP3K19, CDK2, MAP3K1 | HTR6 4036/4885DRD3 2957/4885CYP2C9 1088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.